NASDAQ:LMNX - Luminex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 19.57 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$31.78
▲ +1.89 (6.32%)
1 month | 3 months | 12 months
Get New Luminex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMNX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.00
▲ +19.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Luminex in the last 3 months. The average price target is $38.00, with a high forecast of $38.00 and a low forecast of $38.00. The average price target represents a 19.57% upside from the last price of $31.78.
Buy
The current consensus among 1 investment analysts is to buy stock in Luminex. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2020Piper SandlerInitiated CoverageBuy$38.00Low
i
Rating by William Quirk at Piper Sandler
11/11/2019BTIG ResearchLower Price TargetBuy$32.00Low
i
9/27/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$23.00 ➝ $21.00Low
i
5/7/2019William BlairReiterated RatingMarket PerformLow
i
Rating by B. Weinstein at William Blair
11/6/2018CitigroupLower Price TargetNeutral ➝ Neutral$34.00 ➝ $33.00High
i
8/7/2018Jefferies Financial GroupReiterated RatingHold$27.00High
i
7/23/2018CitigroupBoost Price TargetNeutral ➝ $33.58$23.00 ➝ $34.00Low
i
5/8/2018BTIG ResearchSet Price TargetBuy$26.00High
i
Rating by Sung Ji Nam at BTIG Research
5/7/2018Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$22.00High
i
2/13/2018William BlairReiterated RatingMarket PerformLow
i
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$24.00High
i
10/20/2017Jefferies Financial GroupReiterated RatingHold$21.00N/A
i
6/9/2017Jefferies Financial GroupReiterated RatingHold$21.00Low
i
5/2/2017Jefferies Financial GroupBoost Price TargetHold$20.00 ➝ $21.00Medium
i
2/14/2017Jefferies Financial GroupReiterated RatingHold$20.00N/A
i
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 ➝ $19.00N/A
i
2/7/2017William BlairReiterated RatingMarket PerformN/A
i
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingSell$18.00N/A
i
11/1/2016William BlairReiterated RatingMarket PerformN/A
i
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/A
i
8/18/2016JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$18.00 ➝ $22.00N/A
i
7/28/2016Jefferies Financial GroupBoost Price TargetHold$21.00 ➝ $23.00N/A
i
5/3/2016Piper Jaffray CompaniesReiterated RatingHold$19.00 ➝ $20.00N/A
i
Rating by William Quirk at Piper Jaffray Companies
5/3/2016SVB LeerinkReiterated RatingHold$22.00N/A
i
(Data available from 3/3/2016 forward)
Luminex logo
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More

Today's Range

Now: $31.78
$29.12
$33.66

50 Day Range

MA: $28.75
$25.80
$32.99

52 Week Range

Now: $31.78
$20.61
$41.69

Volume

3,524,312 shs

Average Volume

731,079 shs

Market Capitalization

$1.48 billion

P/E Ratio

81.49

Dividend Yield

1.34%

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Luminex?

The following Wall Street analysts have issued reports on Luminex in the last year: Piper Sandler, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for LMNX.

What is the current price target for Luminex?

1 Wall Street analysts have set twelve-month price targets for Luminex in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 19.6%. Piper Sandler has the highest price target set, predicting LMNX will reach $38.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $38.00 for Luminex in the next year.
View the latest price targets for LMNX.

What is the current consensus analyst rating for Luminex?

Luminex currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LMNX will outperform the market and that investors should add to their positions of Luminex.
View the latest ratings for LMNX.

What other companies compete with Luminex?

How do I contact Luminex's investor relations team?

Luminex's physical mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier's listed phone number is 512-219-8020 and its investor relations email address is [email protected] The official website for Luminex is www.luminexcorp.com.